Oral GLP-1s without fasting or reduced efficacy: Delivery approach protects peptide-based drugs from stomach acid

Biomedical engineers at Duke University have developed a new approach to delivering GLP-1 medications orally that does not require fasting and maintains their efficacy. The technique could also be useful for any pharmaceutical based on peptides such as insulin or treatments for irritable bowel syndrome, HIV and osteoporosis.